#USA #San Diego #Nuravax #AV-1959R #Alzheimer's Vaccine

Nuravax to Present Alzheimer's Vaccine Research at CTAD 2025

Nuravax Inc., a pioneering biopharmaceutical company focused on immunotherapies for neurodegenerative diseases, will showcase significant advancements in its Alzheimer’s vaccine, AV-1959R. Scheduled for December 3-5, 2025, at the Clinical Trials on Alzheimer's Disease (CTAD-25) conference in San Diego, the company will present two oral communications detailing the outcomes of its Phase 1 clinical trial and the design for a Phase 2 secondary prevention study.

Presentation Overview

In a dedicated session titled "Oral Communications – Phase 1," taking place on December 4, 2025, from 2:30 PM to 4:00 PM (PST), the Phase 1 results will be discussed. The main focus will be on how the MultiTEP-based vaccine safely induces a robust immune response, eliciting high concentrations of antibodies specifically targeting amyloid-beta (Aβ) protofibrils, fibrils, and plaques. Among those presenting will be noted experts Michael G. Agadjanyan, Lon Schneider, Alex Grinberg, and Anahit Ghochikyan.

Following this, the same day will feature a discussion on the Phase 2 design for AV-1959R's secondary therapeutic prevention, emphasizing the strategic outlines and considerations necessary for further studies. This segment will be presented by a team including Schneider, Agadjanyan, Ghochikyan, and Roman Kniazev, Nuravax's CEO.

Significance of AV-1959R

AV-1959R stands out due to its unique MultiTEP platform, crafted to tackle immunological tolerance issues by effectively stimulating strong anti-Aβ antibody responses in diverse populations at risk. According to CEO Roman Kniazev, the success of Phase 1 may herald a significant leap in the fight against Alzheimer's, offering genuine promise for active immunization strategies and proactive risk mitigation.

The vaccine is designed as an adjuvanted, amyloid-beta epitope-specific immunization, aimed at triggering high levels of protective antibodies while minimizing the chances of developing harmful autoreactive T cell responses. It targets individuals at risk of Alzheimer's, including those with detectable biomarkers, family histories of the disease, and genetic predispositions like the APOE4 genotype and specific mutations in genes such as APP, PSEN1, PSEN2, TREM2, and CASP8. Furthermore, the vaccine takes into account various comorbid health conditions that may elevate Alzheimer's risk, such as hypertension, hyperlipidemia, type 2 diabetes, and obesity.

About Nuravax

Nuravax is dedicated to advancing immunotherapy options for neurodegenerative diseases, not only for Alzheimer's but also for conditions like Parkinson's and traumatic brain injuries. Its commitment to early intervention remains central to its mission, as the company drives forward in clinical, regulatory, and manufacturing phases, particularly with its dual-target vaccine, Duvax, obtained from the Institute for Molecular Medicine.

For more information about Nuravax and its innovative therapeutic strategies, please visit www.nuravax.com.